Pegunigalsidase
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Clinical Efficacy and Real-World Effectiveness of Fabry Disease Treatments: A Systematic Literature Review.
Journal: Journal of clinical medicine
Published: May 23, 2025
Progress and Challenges in the Treatment of Fabry Disease.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: April 09, 2025
Lysosomal storage diseases in North America: a comprehensive review of enzyme therapies and unmet needs.
Journal: Therapeutic advances in rare disease
Published: February 17, 2025
New Drugs Available for Fabry Disease.
Journal: Kidney & blood pressure research
Published: December 30, 2024
Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry Disease.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: November 04, 2024
Current status of the immunogenicity of enzyme replacement therapy in fabry disease.
Journal: Orphanet journal of rare diseases
Published: October 10, 2024
Establishing Treatment Effectiveness in Fabry Disease: Observation-Based Recommendations for Improvement.
Journal: International journal of molecular sciences
Published: August 02, 2024
Plant molecular farming: a promising frontier for orphan drug production.
Journal: Biotechnology letters
Published: August 01, 2024
Effects of Current Therapies on Disease Progression in Fabry Disease: A Narrative Review for Better Patient Management in Clinical Practice.
Journal: Advances in therapy
Published: July 11, 2024
What is confirmed in the treatment of Fabry's disease?
Journal: Innere Medizin (Heidelberg, Germany)
Published: June 17, 2024
Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials.
Journal: Advances in therapy
Published: April 24, 2024
Last Updated: 02/24/2026